Latest Options News

Rhythm Biosciences has taken a significant step toward commercialising its ColoSTAT blood test for colorectal cancer by enrolling the first physician in its Access Program, marking the transition from clinical trials to routine clinical use.

Critical Resources Limited has launched a six-month evaluation program in partnership with the South Dakota School of Mines & Technology to develop next-generation solid-state lithium-ion battery materials, aiming to reduce technical risks and accelerate prototype development.

Evolution Energy Minerals Limited has announced a renounceable pro-rata entitlement offer to raise up to $4.03 million, aiming to fund exploration and development of its Tanzanian copper and graphite assets. The offer includes free attaching options and is partially underwritten, reflecting both opportunity and risk amid regulatory challenges.

Evolution Energy Minerals has announced a $4 million renounceable entitlement offer priced at 1.5 cents per share, including free attaching options, with major shareholder Metals One Plc committing $1 million.

Alicanto Minerals has finalised a significant 12-for-1 share consolidation, streamlining its capital structure just days before acquiring the Mt Henry Gold Project from Westgold Resources.

Axel REE Limited reports breakthrough metallurgical test results from its Caladão Project in Brazil, achieving over 96% recovery of magnetic rare earth oxides using hydrochloric acid leaching. This milestone supports a dual-path development strategy combining low-cost in situ recovery with a longer-term acid leach option.

AGL Energy Limited has announced a fully franked ordinary dividend of AUD 0.24 per share for the six months ending December 2025, payable in March 2026. This dividend reflects the company’s steady financial footing amid ongoing market challenges.

ASB’s half-year results show a modest 1% rise in cash net profit, driven by growth in home, business, and rural lending alongside a 5% increase in customer deposits. The bank is investing heavily in technology, customer experience, and social housing initiatives to support New Zealand’s long-term prosperity.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

Cosmo Metals Limited has announced a fully underwritten entitlement offer to raise approximately $1.55 million, aimed at advancing drilling and exploration across its key gold and base metals projects. The offer includes new shares and attaching options, with funds earmarked for multiple projects in Western Australia and New South Wales.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

Commonwealth Bank of Australia has announced a fully franked ordinary dividend of AUD 2.35 per share for the half-year ending December 2025, with a Dividend Reinvestment Plan available to shareholders.